

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method of treating an animal to reduce body fat comprising administering to an animal in need thereof a therapeutically effective amount of a phosphodiesterase 9 (PDE9) inhibitor.
2. (Original) A method of claim 1, wherein said mammal is overweight.
3. (Original) A method of claim 1, wherein said mammal is obese.
4. (Original) A method of claim 1, wherein said PDE9 inhibitor is a PDE9 selective inhibitor.
5. (Original) A method of treating an animal for an eating disorder, said method comprising administering to an animal in need thereof a therapeutically effective amount of a PDE9 inhibitor.
6. (Original) A method of claim 5, wherein said PDE9 inhibitor is a PDE9 selective inhibitor.
7. (Original) A genetically-modified mouse, wherein said mouse is homozygous for disruption of the PDE9 gene and wherein said mouse, following a six week high fat diet, exhibits reduced body weight or reduced fat mass in an adipose depot, as compared to a wild type mouse following a six week high fat diet.
8. (Original) A mouse of claim 7, wherein said mouse expresses an exogenous reporter gene under the control of the regulatory sequences of said PDE9 gene.
9. (Original) A mouse of claim 7, wherein said mouse exhibits nondetectable PDE9 activity.
10. (Original) A genetically-modified cultured mammalian cell, wherein said cell is homozygous for disruption of the PDE9 gene and wherein said cell, or a progeny cell derived from said cell, exhibits nondetectable PDE9 polypeptide activity wherein said cell or progeny cell would exhibit PDE9 polypeptide activity absent said homozygous disruption.
11. (Original) A genetically-modified mammalian cell of claim 10, wherein said cell is an embryonic stem (ES) cell.
12. (Original) A genetically-modified cell of claim 11, wherein said cell is a murine ES cell.

13. (Original) A genetically-modified cell of claim 11, wherein said cell is a human ES cell.

14. (Original) A method for producing the mouse of claim 7 comprising:

(a) introducing a DNA sequence into a mouse ES cell, wherein the DNA sequence comprises a PDE9 gene targeting construct, which, upon recombination with the PDE9 gene, disrupts the PDE9 gene;

(b) selecting a mouse ES cell whose genome comprises a disruption of the PDE9 gene;

(c) introducing an ES cell selected in step (b) into a mouse blastocyst or morulae;

(d) transplanting the blastocyst or morulae of step (c) into a foster mother mouse;

(e) developing the transferred blastocyst or morulae to term to produce a chimeric mouse; and

(f) obtaining a mouse homozygous for the PDE11 gene disruption by breeding chimeric mice of step (e) and mice heterozygous for the PDE9 disruption;

wherein said mouse homozygous for disruption of the PDE9 gene, following a six week high fat diet, exhibits reduced body weight or reduced fat mass in an adipose depot, as compared to a wild type mouse following a six week high fat diet.

15. (Original) An isolated nucleic acid molecule comprising a PDE9 gene targeting construct, wherein, upon recombination with the PDE9 gene, said construct disrupts the PDE9 gene.

16. (New) A method of treating an animal to reduce food intake comprising administering to an animal in need thereof a therapeutically effective amount of a phosphodiesterase 9 (PDE9) inhibitor.

17. (New) A method of claim 16, wherein said mammal is overweight.

18. (New) A method of claim 16, wherein said mammal is obese.

19. (New) A method of claim 16, wherein said PDE9 inhibitor is a PDE9 selective inhibitor.